CTOs on the Move

Equiscript

www.equiscript.com

 
Equiscript helps safety net providers better understand and grow their 340B pharmacy business. With a keen eye for detail, our skilled people assist our clients in the design and implementation of a home delivery pharmacy program intended to improve health outcomes by putting much-needed medicines into the hands of those patients in the communities we serve.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.equiscript.com
  • 1360 Truxtun Avenue Suite 300
    North Charleston, SC USA 29405
  • Phone: 843.300.1930

Executives

Name Title Contact Details
Maria Jose Springer
Chief Technology Officer Profile

Similar Companies

Novel Laboratories

Novel Laboratories is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St. Joseph Children's Home

We providing a continuum of care through our three programs: Foster Care and Adoption Program, Residential Treatment Program, and Child Development Center.

ST CATHRINE REGINAL HOSP

Saint Catherine Medical Center Fountain Springs is committed to establishing itself as a center of clinical excellence, the preferred medical center for residents of our region and for physicians to practice, and the regional employer of choice. This

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

OrphoMed Inc

OrphoMed is a San Francisco based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. OrphoMed dimers are protected by composition of matter and method of use patents.